New cloud tool aims to predict dangerous COPD attacks
NCT ID NCT03240315
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is creating a personalized prediction system for acute exacerbations (sudden worsening) of chronic obstructive pulmonary disease (COPD). Over 3 years, researchers will collect health data from 442 COPD patients and healthy volunteers, including breathing tests, symptoms, and immune markers. Using cloud computing and data analysis, they hope to identify who is at risk and when a flare-up might occur, enabling earlier intervention.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a tool that predicts when a COPD patient might have a flare-up, allowing earlier treatment and fewer hospital visits.
- What could go wrong
- This is an observational study, not a treatment trial. The prediction system may not be accurate enough for real-world use, and results may take years to apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
442 people
The number who actually took part.
- Started
-
Aug 2016
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
COPD subjects in China
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients was diagnosed as COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines older than 40 years old. * A signed and dated written informed consent is obtained prior to participation. * Able to comply with the requirements of the protocol and be available for study visits over 3 years. Exclusion Criteria: * A COPD subject will not be eligible for inclusion in this study if any of the following criteria apply: * Known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first CT scan), other than COPD (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis) * Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and Lupus) * Known to be severely alpha-1-antitrypsin deficient * Has experienced a moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) within the last 4 weeks * Having undergone lung surgery (e.g. lung reduction, lung transplant) * Have cancer or have had cancer in the 5 years prior to study entry * Having received a blood transfusion in the 4 weeks prior to study start * Inability to walk * Taking part in a blinded drug study * Having therapy with systemic corticosteroids at inclusion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary disease, chronic obstructive are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.